These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11090078)

  • 1. Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation.
    Cirinnà M; Trotta R; Salomoni P; Kossev P; Wasik M; Perrotti D; Calabretta B
    Blood; 2000 Dec; 96(12):3915-21. PubMed ID: 11090078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant.
    Salomoni P; Wasik MA; Riedel RF; Reiss K; Choi JK; Skorski T; Calabretta B
    J Exp Med; 1998 Jun; 187(12):1995-2007. PubMed ID: 9625759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects.
    Salomoni P; Condorelli F; Sweeney SM; Calabretta B
    Blood; 2000 Jul; 96(2):676-84. PubMed ID: 10887134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac.
    Skorski T; Wlodarski P; Daheron L; Salomoni P; Nieborowska-Skorska M; Majewski M; Wasik M; Calabretta B
    Proc Natl Acad Sci U S A; 1998 Sep; 95(20):11858-62. PubMed ID: 9751755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing.
    Skorski T; Nieborowska-Skorska M; Wlodarski P; Wasik M; Trotta R; Kanakaraj P; Salomoni P; Antonyak M; Martinez R; Majewski M; Wong A; Perussia B; Calabretta B
    Blood; 1998 Jan; 91(2):406-18. PubMed ID: 9427693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Bcr-Abl expression prevents the translocation of Bax and Bad to the mitochondrion.
    Keeshan K; Cotter TG; McKenna SL
    Leukemia; 2002 Sep; 16(9):1725-34. PubMed ID: 12200687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL.
    Amarante-Mendes GP; McGahon AJ; Nishioka WK; Afar DE; Witte ON; Green DR
    Oncogene; 1998 Mar; 16(11):1383-90. PubMed ID: 9525737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
    Perkins C; Kim CN; Fang G; Bhalla KN
    Blood; 2000 Feb; 95(3):1014-22. PubMed ID: 10648417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate apoptosis response gene-4 (par-4) abrogates the survival function of p185(BCR-ABL) in hematopoietic cells.
    Kukoc-Zivojnov N; Puccetti E; Chow KU; Bergmann M; Ruthardt M; Hoelzer D; Mitrou PS; Weidmann E; Boehrer S
    Exp Hematol; 2004 Jul; 32(7):649-56. PubMed ID: 15246161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.
    Skorski T; Bellacosa A; Nieborowska-Skorska M; Majewski M; Martinez R; Choi JK; Trotta R; Wlodarski P; Perrotti D; Chan TO; Wasik MA; Tsichlis PN; Calabretta B
    EMBO J; 1997 Oct; 16(20):6151-61. PubMed ID: 9321394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis.
    Nieborowska-Skorska M; Wasik MA; Slupianek A; Salomoni P; Kitamura T; Calabretta B; Skorski T
    J Exp Med; 1999 Apr; 189(8):1229-42. PubMed ID: 10209040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. G-protein coupled receptor 34 activates Erk and phosphatidylinositol 3-kinase/Akt pathways and functions as alternative pathway to mediate p185Bcr-Abl-induced transformation and leukemogenesis.
    Zuo B; Li M; Liu Y; Li K; Ma S; Cui M; Qin Y; Zhu H; Pan X; Guo J; Dai Z; Yu W
    Leuk Lymphoma; 2015 Jul; 56(7):2170-81. PubMed ID: 25363403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis.
    Perrotti D; Bonatti S; Trotta R; Martinez R; Skorski T; Salomoni P; Grassilli E; Lozzo RV; Cooper DR; Calabretta B
    EMBO J; 1998 Aug; 17(15):4442-55. PubMed ID: 9687511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated abl oncogenes and apoptosis: differing responses of transformed myeloid progenitor cell lines.
    Zhu J; Nabissa PM; Hoffman B; Liebermann DA; Shore SK
    Blood; 1996 May; 87(10):4368-75. PubMed ID: 8639797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line.
    Ahmed M; Dusanter-Fourt I; Bernard M; Mayeux P; Hawley RG; Bennardo T; Novault S; Bonnet ML; Gisselbrecht S; Varet B; Turhan AG
    Oncogene; 1998 Jan; 16(4):489-96. PubMed ID: 9484838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2.
    Sánchez-García I; Grütz G
    Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5287-91. PubMed ID: 7777499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
    Dai Y; Rahmani M; Corey SJ; Dent P; Grant S
    J Biol Chem; 2004 Aug; 279(33):34227-39. PubMed ID: 15175350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3.
    Amarante-Mendes GP; Naekyung Kim C; Liu L; Huang Y; Perkins CL; Green DR; Bhalla K
    Blood; 1998 Mar; 91(5):1700-5. PubMed ID: 9473236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.
    Nieborowska-Skorska M; Slupianek A; Skorski T
    Oncogene; 2000 Aug; 19(36):4117-24. PubMed ID: 10962572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
    Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
    Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.